'Creed' and 'Black Panther' star Michael B. Jordan has been named PEOPLE magazine's Sexiest Man Alive for 2020.
'Creed' and 'Black Panther' star Michael B. Jordan has been named PEOPLE magazine's Sexiest Man Alive for 2020.
Fred Taylor knows he beat a lot of defensive players who are currently in the Hall of Fame.
With coronavirus cases spiking in the U.S. and Europe, the financial outlook of the world’s airlines is getting worse. The forecast from the International Air Transport Association was worse than the group's June estimate of $100 billion in losses for the two years. The latest estimate breaks down to airlines losing $66 for every passenger carried this year.
Griffon Corporation ("Griffon" or the "Company") (NYSE:GFF) today announced it will present at the Bank of America 2020 Leveraged Finance Conference on Tuesday, December 1, 2020. The conference will be held in a virtual format. A copy of Griffon’s investor presentation, which will be used for the conference, will be available at the time of the conference in the investor relations section of Griffon’s website (www.griffon.com).
Floor & Decor Holdings, Inc. (NYSE: FND) today announced that the Company is scheduled to present at the Morgan Stanley Global Consumer & Retail Conference on Wednesday, December 2, 2020, at 2:00 pm Eastern Time.
Glu Mobile Inc. (NASDAQ: GLUU), a leading developer and publisher of mobile games, today announced that Nick Earl, President and Chief Executive Officer, and Eric R. Ludwig, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in the following upcoming virtual conferences:
Among the multitude of products, find crop tops, leggings, select outerwear and accessories all on sale.
The Rays' postseason star has been detained in Mexico over an alleged family dispute.
The NFL has set its pairings for the league's first Saturday doubleheader this season. The Buffalo Bills will visit the Denver Broncos on Dec. 19 at 4:30 p.m. ET. The NFL had five games to choose from for the first Saturday doubleheader with teams told only that they would play either Dec. 19 or Dec. 20 when the league announced schedules earlier this year.
NetApp (NASDAQ: NTAP), a global cloud-led, data centric software company, today announced the Company will participate virtually in fireside chats at the following conferences:
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $39.00 per share. The net proceeds from the offering were approximately $105.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Raven Industries (NASDAQ:RAVN) today reported financial results for the third quarter that ended October 31, 2020.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
Michelle Clatterbuck, chief financial officer of Intuit (Nasdaq: INTU) will present at the Credit Suisse Technology Virtual Conference on Dec. 1.
American Eagle Outfitters, Inc. (NYSE: AEO) today reported operating income of $96 million for the 13 weeks ended October 31, 2020, compared to $103 million for the 13 weeks ended November 2, 2019. Adjusted operating income of $103 million this year excluded $7 million of expenses primarily related to COVID-19 protocols.
Tampa, FL, 11/24/2020 / 16:00, EST/EDT - EQS Newswire - The Mosaic Company TAMPA, FL / ACCESSWIRE / November 24, 2020 / The U.S. Department of Commerce announced today that it preliminarily found that phosphate fertilizer imports from Morocco and Russia benefit from countervailable subsidies. Commerce calculated a subsidy rate of 23.46 percent for Moroccan producer OCP. In the Russia investigation, Commerce calculated rates of 20.94 percent and 72.5 percent for the PhosAgro and EuroChem respondent entities, respectively, and a rate of 32.92 percent for all other producers/exporters. Beginning in a matter of days, the rates from Commerce's preliminary determinations will be used to impose preliminary cash deposits on Moroccan and Russian phosphate fertilizer imports into the United States. "We appreciate the Commerce Department's diligent work on our countervailing duty petitions," said Mosaic President and CEO Joc O'Rourke. "Mosaic believes in vigorous competition and free and fair trade, and that these foreign government subsidies must be addressed in order to level the playing field in the U.S. market. Today's ruling moves a step closer to fair trade and an assurance for U.S. farmers that they will be able to rely on U.S. fertilizer for decades to come." U.S. law provides remedies to American manufacturers against unfair and injurious foreign trade practices. Commerce's investigations of Moroccan and Russian phosphate fertilizer imports will now proceed to final determinations, which are scheduled to be issued by February 8, 2021. In a parallel proceeding, the U.S. International Trade Commission is investigating whether Moroccan and Russian phosphate fertilizer imports materially injure the U.S. phosphate fertilizer industry, and its final determinations are scheduled to be issued by March 25, 2021. About The Mosaic Company The Mosaic Company is one of the world's leading producers and marketers of concentrated phosphate and potash crop nutrients. Mosaic is a single-source provider of phosphate and potash fertilizers and feed ingredients for the global agriculture industry. More information on the company is available at www.mosaicco.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the anticipated benefits or strategic plans and other statements about anticipated future financial, production and operating performance. Such statements are based upon the current beliefs and expectations of The Mosaic Company's management and are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to: difficulties with realization of the benefits or strategic plans; actual costs of various items differing from management's current estimates, price and demand volatility for our products, other changes in market conditions, accidents and disruptions, including potential mine fires, floods, explosions, seismic events, sinkholes or releases of hazardous or volatile chemicals; changes in foreign currency and exchange rates; international trade risks and other risks associated with Mosaic's international operations, changes in government policy, changes in environmental and other governmental regulation, as well as other risks and uncertainties reported from time to time in The Mosaic Company's reports filed with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Media Ben Pratt The Mosaic Company 813-775-4206 firstname.lastname@example.org Investors Laura Gagnon The Mosaic Company 763-577-8213 email@example.com SOURCE: The Mosaic Company 11/24/2020 EQS Newswire / EQS Group AG
Corrections and clarificationsModerna Covid-19 vaccine | Longmeadow
Black Friday GizmoWatch deals for 2020 are finally here, find all the best Black Friday Verizon Gizmo Watch smartwatch savings right here
The Elevated Spirits Company is pleased to announce that Cierto Tequila was honored with an incredible six (6) medals at the 2020 Melbourne International Spirits Competition (MISC). The MISC honored Cierto with two Gold medals, one Silver medal, two Bronze medals and named Cierto Tequila the "Distiller of the Year." With these six new medals and awards, Cierto Tequila has now won two hundred and thirty-one (231) international medals and awards - far surpassing all other tequila brands. Cierto Tequila is an authentic, 100% natural "true" tequila made exclusively from healthy, mature highland agave in Jalisco, Mexico. Due to its character, complexity and incredibly smooth taste, tequila experts around the globe have called Cierto the "World’s Finest Tequila."
Sasan Goodarzi, chief executive officer of Intuit (Nasdaq: INTU) will present at the 43rd Nasdaq Investor Virtual Conference on Dec. 1.
Daix (France), November 24, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. During the conference, Inventiva will engage in 1x1 investor meetings as well as in a fire-side chat with an analyst from Piper Sandler. The event details are as follows: Format: Analyst fireside chatSpeakers: Frédéric Cren, Chairman, CEO and cofounder of Inventiva, and Pierre Broqua, Chief Scientific Officer and cofounder of InventivaReplay link (available as of now): https://pipersandler.zoom.us/rec/play/jN7bcT_RWHs6wFUWvRTd2cOENx4J6KOawInzHhY6Bd8BZ-WLH1hvHPJPy7ct5Ns737Qr6dp2ZGY5yvxG.TT4iwmadZzEQ_McZ The link to the event will also be available on Inventiva’s website in the “Investors – Investor Presentations” section. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts Inventiva Frédéric Cren Chairman & CEO firstname.lastname@example.org +33 3 80 44 75 00 Brunswick Group Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux Media relations email@example.com +33 1 53 96 83 83 Westwicke, an ICR Company Patricia L. Bank Investor relations firstname.lastname@example.org +1 415 513 1284 Attachment Inventiva - PR - Piper Sandler 32nd Annual Virtual Healthcare Conference - EN - 24 11 20